| 3.04 -0.09 (-2.88%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.35 | 1-year : | 4.87 |
| Resists | First : | 3.72 | Second : | 4.17 |
| Pivot price | 3.62 |
|||
| Supports | First : | 3 | Second : | 2.49 |
| MAs | MA(5) : | 3.25 |
MA(20) : | 3.7 |
| MA(100) : | 3.09  |
MA(250) : | 2.07 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.3 |
D(3) : | 15.2 |
| RSI | RSI(14): 32.7 |
|||
| 52-week | High : | 4.17 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ESPR ] has closed above bottom band by 0.9%. Bollinger Bands are 54.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.19 - 3.22 | 3.22 - 3.24 |
| Low: | 2.97 - 3.01 | 3.01 - 3.03 |
| Close: | 3 - 3.06 | 3.06 - 3.1 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Wed, 14 Jan 2026
ESPR: Vision 2040 targets global expansion, pipeline growth, and sustainable profitability by 2026 - TradingView — Track All Markets
Tue, 13 Jan 2026
Esperion Therapeutics Faces Financial Challenges Amid Market Uncertainty - StocksToTrade
Sun, 11 Jan 2026
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Tue, 25 Nov 2025
Esperion Therapeutics: Soaring Momentum Observed - StocksToTrade
Tue, 25 Nov 2025
Piper Sandler Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - Nasdaq
Mon, 10 Nov 2025
Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 237 (M) |
| Shares Float | 235 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 47.2 (%) |
| Shares Short | 28,830 (K) |
| Shares Short P.Month | 24,960 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.21 |
| Profit Margin | -34.9 % |
| Operating Margin | -11.5 % |
| Return on Assets (ttm) | -5.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 69 % |
| Gross Profit (p.s.) | 0.55 |
| Sales Per Share | 1.28 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -93 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -5.63 |
| PEG Ratio | 0 |
| Price to Book value | -1.39 |
| Price to Sales | 2.37 |
| Price to Cash Flow | -7.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|